A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Because patients with beta-thalassemia are unable to actively eliminate iron from the body,
toxic and eventually lethal levels of iron can accumulate as a result of repeated blood
transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.